| USAN | Research Code | Structure | Drug Class | Therapeutic class | Target |
| avarofloxacin |
JNJ-Q2, JNJ-32729463-AAA
| synthetic small molecule | therapeutic | topo II | |
| dianexin | ASP-8597 | protein | therapeutic | ||
| eldelumab |
BMS-936557, MDX-1100
| monoclonal antibody | therapeutic | CXCL10 | |
| eluxadoline |
JNJ-27018966
| synthetic small molecule | therapeutic | mu Opioid R, delta Opioid R | |
| formofilcon A | polymer | contact lens polymer | n/a | ||
| galunisertib |
LY-2157299
| synthetic small molecule | therapeutic | TGFBetaR1 TGFBetaR2 | |
| guselkumab |
CNTO-1959
| monoclonal antibody | therapeutic | IL23 | |
| ledipasvir | GS-5885 | synthetic small molecule | therapeutic | HCV NS5A | |
| liafensine | BMS-820836 | synthetic small molecule | therapeutic | ||
| margetuximab |
MGAH22
| monoclonal antibody | therapeutic | ERBB2 | |
| mavatrep |
JNJ-39439335
| synthetic small molecule | therapeutic | ||
| methylsamidorphan |
ALKS-37, RDC-1036-00
| natural product-derived small molecule | therapeutic | Opioid receptors | |
| palbociclib |
PD-0332991
| synthetic small molecule | therapeutic | CDK4 CDK6 | |
| pegbovigrastim |
LY-2953726
| protein | therapeutic | CSFR | |
| pevonedistat | MLN-4924 | synthetic small molecule | therapeutic | NAE | |
| quilizumab |
RG-7449, MEP-1972A, Anti-M1’, Anti-M1 prime
| monoclonal antibody | therapeutic | IgE M1' | |
| sisapronil | PF-0241851 | synthetic small molecule | therapeutic | ||
| technetium Tc 99m trofolastat |
MIP-Tc-1404, MIP-99mTc-1404
| synthetic small molecule | imaging agent | PSMA | |
| tovetumab | MEDI-575 | monoclonal antibody | therapeutic | PDGFRa | |
| vantictumab |
OMP-18R5
| monoclonal antibody | therapeutic | Frizzled | |
| vatiquinone | EPI-743 | synthetic small molecule | therapeutic | NQO1 | |
| vedroprevir | GS-9451 | synthetic small molecule | therapeutic | HCV NS3 PR |
jpo
2 comments:
One interesting name that Gilead has just started using is idealisib for GS-1101, a PI3Kdelta inhibitor.
This doesn't yet appear to be a INN or USAN
I would be surprised if this is allowed as a USAN/INN since it implies some performance judgement. The AMA website has this statement...
Specific nomenclature rules
1. Prefixes that imply "better," "newer" or "more effective;" prefixes that evoke the name of the spnsor, dosage form, duration of action or rate of drug release should not be used. Examples include "dura," "forte," or "efex."
But they may be trying it on over the difference between idea-lisib and ideal-isib - the first of course follows the stem rule. If they allow this - whatever next - longadafanil?
Post a Comment